Farnesyltransferase inhibitors

Breast Cancer Research

Volumn 6, Issue 6, 2004, Pages 262-268

  Head, Julia ^a   Johnston, Stephen R D ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Breast cancer; Farnesyltransferase inhibitors

Indexed keywords

2 [[2 [[2 [(2 AMINO 3 MERCAPTOPROPYL)AMINO] 3 METHYLPENTYL]OXY] 1 OXO 3 PHENYLPROPYL]AMINO] 4 (METHYLSULFONYL)BUTANOIC ACID ISOPROPYL ESTER; 3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; ANASTROZOLE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; BMS 186511; CAPECITABINE; CARBOPLATIN; CELL PROTEIN; CISPLATIN; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; FULVESTRANT; GEFITINIB; L 778123; LETROZOLE; LONAFARNIB; N [[5 [(2 AMINO 3 MERCAPTOPROPYL)AMINO][1,1' BIPHENYL] 2 YL]CARBONYL]METHIONINE METHYL ESTER; PACLITAXEL; PLACEBO; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RAS PROTEIN; TAMOXIFEN; TAXANE DERIVATIVE; TIPIFARNIB; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE; ENZYME INHIBITOR; FARNESYL TRANS TRANSFERASE; TRANSFERASE;

ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CELL CULTURE; CANCER CONTROL; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER INHIBITION; CANCER RESISTANCE; CLINICAL TRIAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DESIGN; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG SYNTHESIS; DRUG TARGETING; DRUG TOLERABILITY; FATIGUE; GASTROINTESTINAL TOXICITY; HUMAN; METASTASIS; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; PERIPHERAL NEUROPATHY; REVIEW; SIGNAL TRANSDUCTION; SYSTEMIC THERAPY; THROMBOCYTOPENIA; ANIMAL; BREAST TUMOR; DRUG ANTAGONISM; DRUG SCREENING; ENZYMOLOGY; TUMOR CELL LINE;

ALKYL AND ARYL TRANSFERASES; ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CLINICAL TRIALS; ENZYME INHIBITORS; FARNESYLTRANSTRANSFERASE; HUMANS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 7444232526     PISSN: 14655411     EISSN: None     Source Type: Journal    
DOI: 10.1186/bcr947     Document Type: Review

References (55)

1. Clark GJ, Der CJ: Aberrant function of the Ras signal transduction pathway in human breast cancer. Breast Cancer Res Treat 1995, 35:133-144.
2. Norgaard P, Law B, Joseph H, Page DL, Shyr Y, Mays D, Pietenpol JA, Kohl NE, Oliff A, Coffey RJ, et al.: Treatment with farnesyl-protein transferase inhibitor induces regression of mammary tumors in transforming growth factor (TGF) alpha and TGF alpha/neu transgenic mice by inhibition of mitogenic activity and induction of apoptosis. Clin Cancer Res 1999, 5: 35-42.
3. Clark GJ, Kinch MS, Gilmer TM, Burridge K, Der CJ: Overexpression of the Ras-related TC21/R-Ras2 protein may contribute to the development of human breast cancers. Oncogene 1996, 12: 69-176.
4. Casey PJ, Seabra MC: Protein prenyltransferases. J Biol Chem 1996, 271:5289-5292.
5. Marshall CJ: Cell signalling; Raf gets it together. Nature 1996, 383:127-128.
6. Kennedy SG, Wagner AJ, Conzen SD, Jordan J, Bellacosa A, Tsichlis PN, Hay N: The PI3-kinase/Akt sinaling pathway delivers an anti-apoptotic signal. Genes Dev 1997, 11:701-713.
7. Lange-Carter CA, Pleiman CM, Gardner AM, Blumer KJ, Johnson GL: A divergence in the MAP kinase regulatory network defined by MEK kinase and Raf. Science 1993, 260:315-319.
8. Kato K, Cox AD, Hisaka MM, Graham SM, Buss JE, Der CJ: Isoprenoid addition to ras protein is the critical modification for its membrane association and transforming activity. Proc Natl Acad Sci USA 1992, 89:6403-6407.
9. Sepp-Lorenzino L, Ma Z, Rands E, Khol NE, Gibbs JB, Rosen NA: A peptidomimetic inhibitor of farnesyl protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines. Cancer Res 1995, 55:5302-5309.
10. Khol NE, Omer CA, Conner MW, Anthony NJ, Davide JP, DeSolms SJ, Giuliani E, Gomez RP, Graham SL, Hamilton K, et al.: Inhibition of farnesyltransferase induces regression of mammaruy and salivary carcinomas in ras transgenic mice. Nat Med 1995, 1: 92-797.
11. Qian Y, Blaskovich MA, Saleem M, Seong CM, Wathen SP, Hamilton AD, Sebti SM: Design and structural requirements of potent peptidomimetics inhibitors of p21ras farnesyltransferase. J Biol Chem 1994, 269:12410-12413.
12. Bishop WR, Bond R, Petrin J, Wang L, Patton R, Doll R, Njoroge G, Catino J, Schwartz J, Windsor W, et al.: Novel tricyclic inhibitors of farnesyl protein transferase. J Biol Chem 1995, 270:30611-30618.
13. End DW, Smets G, Todd AV, Applegate TL, Fuery CJ, Angibaud P, Venet M, Sanz G, Poignet H, Skrzat S, et al.: Characterisation of the antitumor effects of the selective farnesyl protein transferase inhbitor R115777 in vivo and in vitro. Cancer Res 2001, 61: 31-137.
14. Johnston SRD: BMS-214662: a novel farnesyl transferase inhibitor. Curr Opin Invest Drugs 2003, 6:72-78.
15. Britten CD, Rowinsky E, Yao S-L, Soignet S, Rosen N, Eckhardht SG, Drengler R, Hammond L, Siu LL, Smith L, et al.: The farnesyl protein transferase (FTPase) inhibitor L-788,123 in patients with solid cancers [abstract]. Proc Am Soc Clin Oncol 1999, 18:A597.
16. Prendergast GC, Davide JP, deSolms SJ, Giuliani E, Graham SL, Gibbs JB, Oliff A, Khol NE: Farnesylytransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of actin cytoskeleton. Mol Cell Biol 1994, 14:4193-4202.
17. Miquel K, Pradines A, Sun J, Qian Y, Hamilton AD, Sebti SM, Favre G: GGTI-298 induces G0-G1 block and apoptosis wheras FTI-277 causes G2-M enrichment in A549 cells. Cancer Res 1997, 57: 846-1850.
18. Sepp-Lorenzino L, Rosen N: A farnesyl-protein transferase inhibitor induces p21 expression and G1 block in p53 wild-type tumor cells. J Biol Chem 1998, 273:20243-20251.
19. Kelland LR, Smith V, Valenti M, Patterson L, Clarke PA, Detre S, End DW, Howes AJ, Dowsett M, Workman P, et al.: Preclinical antitumor activity and pharmacodynamic studies with the farnesyl protein transferase inhibitor R115777 in human breast cancer. Clin Cancer Res 2001, 7:3544-3550.
20. Du W, Liu A, Prendergast GC: Activation of the PI3'K-AKT pathway masks the pro-apoptotic effects of farnesyltransferase inhibitors Cancer Res 1999, 59:4208-4212.
21. Cox AD, Der CJ: Farnesyltransferase inhibitors and cancer treatment: tageting simply ras? Biochem Biophys Acta 1997, 1333:F51 -F71.
22. Ashar HR, James L, Gray K, Carr D, Black S, Armstrong L, Bishop WR, Kirschmeier P: Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CNEP-E with the microtubules. J Biol Chem 2000, 39: 30451-30457.
23. James GL, Goldstein JL, Pathak RK, Anderson RG, Brown MS: PxF, a prenylated protein of perioxsomes. J Biol Chem 1994, 269:14182-14190.
24. Farnsworth CC, Wolda SL, Gelb MH, Glomset JA: Human lamin B contains a farnesylated cysteine residue. J Biol Chem 1989, 264:20422-20429.
25. Jiang K, Coppola D, CresPo NC: The phosphoinositide 3-OH kinase/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis. Mol Cell Biol 2000, 20: 139-148.
26. Liu A, Du W, Liu JP, Jessel TM, Prendergast GC: RhoB alteration is necessary for apoptotic and antineoplastic response to farnesyltransferase inhibitors. Mol Cell Biol 2000, 20:6105-6113.
27. Adeji AA: Protein farnesyl transferase as a target for the development of anticancer agents. Drugs Future 2000, 25: 1069-1079.
28. Moasser MM, Sepp-Lorenzino L, Khol NE, Oliff A, Balog A, Su DS, Danishefsky SJ, Rosen NA: Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones. Proc Natl Acad Sci USA 1998, 95:1369-1374.
29. Shi B, Yaremko B, Hajian G, Terracina G, Bishop WR, Liu M, Nielsen LJ: he farnesyl protein transferase inhibitor SCH66336 synergises with taxanes in vitro and enhances their antitumor activity in vivo. Cancer Chemother Pharmacol 2000, 46:387-393.
30. Skrazt SG, Bowden CR, End DW: Interaction of the farnesyly protein transferase inhibitor R115777 with cytotoxic chemotherapeutics in vitro and in vivo [abstract]. Proc Am Assoc Cancer Res 1999, 40:523 (A3447).
31. Nicholson RI, McClelland RA, Robertson JRF, Gee JMW: Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer. Endocr Relat Cancer 1999, 6: 73-387.
32. Bunone G, Briand P, Miksicek R, Picard D: Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J 1996, 15:2174-2183.
33. Simoncini T, Hafezi-Moghadam A, Brazil DP, Ley K, Chin WW, Liao JK: Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 2000, 407:538-541.
34. Gee JMW, Robertson JFR, Ellis IO, Nicholson RI: Phosphorylation of erk 1/2 mitogen activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer. Int J Cancer 2001, 95: 247-254.
35. Martin L-A, Farmer I, Johnston SRD, Ali S, Marshall C, Dowsett M: Enhanced estrogen receptor (ER) aplha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long-term estrogen deprivation. J Biol Chem 2003, 278: 0458-30468.
36. Kurokawa H, Lenferink AEG, Simpson JF, Pisacane PI, Sliwkowski MX, Forbes JT, Arteaga CL: Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Res 2000, 60:5887-5894.
37. Gee JM, Harper ME, Hutcheson IR, Madden TA, Barrow D, Knowlden JM, McClelland RA, Jodan N, Wakeling AE, Nicholson RI: The anti-EGFR agent gefitinib (ZD 1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro. Endocrinology 2003, 144:5105-5117.
38. Shou J, Massaraweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, Schiff R: Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 2004, 96:926-935.
39. Nicholson RI, Hutcheson IR, Knowlden JM, Jones HE, Harper ME, Jordan N, Hiscox SE, Barrow D, Gee JMW: Nonendocrine pathways and endocrine resistance; observations with antiestrogens and signal transduction inhibitors in combination. Clin Cancer Res 2004, 10:346s-354s.
40. Johnston SRD, Head J, Valenti M, Detre S, Dowsett M: Endocrine therapy combined with the farnesyltransferase inhibitor R115777 produces enhanced tumour growth inhibition in hormone-sensitive MCF-7 human breast cancer xenografts in-vivo [abstract]. Breast Cancer Res Treat 2002, 76:A245.
41. Ellis CA, Vos MD, Wickline M, Riley C, Vallecorsa T, Telford WG, Zujewski J, Clark GJ: Tamoxifen and the farnesyl transferase inhibitor FTI-2777 synergise to inhibit growth in estrogen receptor positive breast tumor cell lines. Breast Cancer Res Treat 2003, 78:59-67.
42. Long BJ, Liu G, Marrinan CH, Maxwell E, Black S, Gheyas F, Nomeir A, Liu M, Kirschmeier P, Bishop R: Combining the farnesyl transferase inhibitor (FTI) Lonafarnib (SCH66336) with antiestrogens and aromatase inhibitors results in enhanced growth inhibition of hormone-dependent human breast cancer calls and tumor xenografts [abstract]. Proc Am Assoc Cancer Res 2004, 45:A3868.
43. Doisneau-Sixou SF, Cestac P, Faye J-C, Favre G, Sutherland RL: Additive effects of tamoxifen and the farnesyl transferase inhibitor FTI-277 on inhibition of MCF-7 breast cancer cell cycle progression. Int J Cancer 2003, 106:789-798.
44. Cunningham D, de Gramont A, Scheithauer W, Smakal M, Humblet Y, Kurteva G, Iveson T, Andre T, Dostalova J, Illes A, Jia X, Palmer P: Randomized double-blind placebo controlled trial of the farnesyltransferase inhibitor R-115777 (Zarnestra) in advanced refractory colorectal cancer. Proc Am Soc Clin Oncol 2002, 21:A502.
45. Van Cutsem E, van de Velde H, Karasek P, Oettle H, Vervenne WL, Szawlowski A, Schoffski P, Post S, Verslype C, Neumann H, et al. Phase III Trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer (PC). J Clin Oncol 2004, 22:1430-1438.
46. Lobell RB, Liu D, Buser CA, Davide JP, DePuy E, Hamilton K, Koblan KS, Lee Y, Mosser S, Motzel SL, et al.: Preclinical and clinical pharmacodynamic assessment of L-788,123, a dual inhibitor of farnesyl protein transferase and geranylgeranyl protein transferase-type-1. Mol Cancer Ther 2002, 9:747-758.
47. Adjei AA, Erlichman C, Davis JD, Cutler DL, Sloan JA, Marks RS, Hanson LJ, Svingen PA, Atherton P, Bishop R, et al.: A phase I trial of the farnesyl transferase inhibitor SCH66336; evidence for biological and clinical activity. Cancer Res 2000, 60: 871-1877.
48. Eskens F, Awada A, Cutler DL, deJonge MJA, Luyten GPM, Faber MN, Statkevich P, Sparreboom A, Verweij J, Hanauske A, et al.: Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily in patients with advanced solid tumors. J Clin Oncol 2001, 19:1167-1175.
49. Hudes G, Schol J, Baab J, Rogatko, Bol C, Horak I, Langer C, Goldstein LJ, Szarka C, Meropol NJ, Weiner L: Phase I clinical and pharmacokinetic trial of the farnesylytransferase inhibitor R115777 on a 21-day dosing schedule [abstract]. Proc Am Soc Clin Oncol 1999, 18:A601.
50. Johnston SRD, Hickish T, Ellis PA, Houston S, Kelland LR, Dowsett M, Salter J, Michiels B, Perez-Ruixo JJ, Palmer PA, et al.: Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyltransferase inhibitor R115777 (Zarnestra) in patients with advanced breast cancer. J Clin Oncol 2003, 21:2492-2499.
51. Head J, Johnston SRD: Protein farnesyltransferase inhibitors. Expert Opin Emerg Drugs 2003, 8:163-178.
52. Khuri F, Glisson BS, Kim ES, Statkevich P, Thall PF, Meyers ML, Herbst RS, Munden RF, Tendler C, Zhu Y, et al.: Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxele in solid tumours. Clin Cancer Res 2004, 10:2968-2976.
53. Piccart MJ, Branie F, de Valeriola D, Dubuisson M, Hennebert P, Gil T, Forget F, Seifert W, Thibault A, Bol C, et al.: A phase I clinical and pharmacokinetic trial of the farnesyl transferase inhibitor R115777 + docetaxel; a promising combination in patients with solid tumours [abstract]. Proc Am Soc Clin Oncol 2001, 20: 0a (A318).
54. Holden SN, Eckhardht S, Fisher S, Persky M, Mikule C, O'Bryant CL, Morrow M, Richards H, Rodriquez S, Boi C, et al.: A phase I pharmacokinetic and biological study of the farnesyl transferase inhibitor R115777 and capecitabine in patients with advanced solid malignancies [abstract]. Proc Am Soc Clin Oncol 2001, 20: 0a (A316).
55. Lebowitz PF, Eng-Wong J, Balis F, Widemann B, Jayaprakash N, Gantz S, Chow C, Merino M, Zujewski J: A phase I trial of tipifarnib, a farnesyltransferase inhibitor, and tamoxifen in hormone-receptor positive metastatic breast cancer [abstract]. Proc Am Soc Clin Oncol 2004, 23:37 (A644).